Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury [Phase 2]

View source ↗

Summary

Phase 2 study AVP-786 for neurobehavioral disinhibition in adults with traumatic brain injury has completed enrollment and posted results. Results were posted o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurobehavioral Disinhibition
• Traumatic Brain Injury

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Neurobehavioral Disinhibition | Phase 2 | Status: COMPLETED | Results posted: 2025-10-29